



## Innate and Adaptive Immune Response against Human Herpesviruses

Guest Editors:

**Dr. Chaoran Yin**

Fox Chase Cancer Center,  
Philadelphia, PA, USA

**Dr. Ting Zhang**

Laboratory of Liver  
Transplantation, West China  
Hospital, Sichuan University,  
Chengdu, China

Deadline for manuscript  
submissions:

**31 May 2024**

### Message from the Guest Editors

Dear Colleagues,

Human herpesviruses (HHVs) are widely investigated as they mainly cause cutaneous disease and multiple pathologic abnormalities, and even have oncogenic properties. HHVs are known for their remarkable capacity to establish lifelong latent infections in human hosts, evading host immune surveillance through sophisticated mechanisms. The immune system employs both innate and adaptive immunity as fundamental defense mechanisms against infections. Innate immune cells utilize pattern recognition receptors (PRRs) to initiate an inflammatory response. On the other hand, adaptive immunity relies on the recognition of antigens by B and T cells, leading to the generation of specific immune responses. Among these responses, effector cells such as T helper cells and cytotoxic T lymphocytes play pivotal roles in effectively combating infections.

By conducting specialized research in understanding immune system processes, ongoing research is necessary, we can bolster immune responses and develop more effective strategies to combat HHVs. To achieve these purposes, we cordially invite contributions of original articles or reviews.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)